DOCK8 Awareness

Only a few hundred cases have been reported worldwide. A 2017 review tallied ~230 cases; a 2024 systematic review collated 203 confirmed case reports (under-counting is likely). In other words: still exceptionally rare.
PMC

South Africa: We could not identify any published South African case reports as of September 25, 2025. That doesn’t prove none exist, only that none appear in the medical literature we searched. We’ll update this if experts in SA PID/immunology share data.

Children with DOCK8 don’t just get “ordinary” infections — their bodies are under constant, severe attack because their immune systems are broken. Warning signs include:

• Severe skin disease and viral infections: painful, disfiguring outbreaks of molluscum contagiosum on the face and eyes, repeated cold sores and shingles (HSV, VZV), and chronic eczema or dermatitis that never heals.
• Recurrent lung and sinus infections: frequent chest infections and pneumonias that cause permanent lung damage, along with chronic sinus disease. Over time, bacteria often become resistant to antibiotics, leaving fewer and fewer treatment options.
• Sepsis risk: once infections escape control, bacteria or fungi can spread into the bloodstream, causing sepsis — a life-threatening condition that requires intensive care and can be fatal within hours.
• Allergy and atopy: asthma, multiple food and environmental allergies, with blood tests often showing extremely high IgE levels and eosinophilia (markers of immune dysregulation).
• Cancer and autoimmunity risks: as children grow older, the risk of lymphoma, squamous cell carcinoma, and autoimmune complications rises dramatically.

Without a transplant, these problems worsen each year. What begins as infections doctors can manage eventually become untreatable, pushing the children into cycles of hospitalization, sepsis risk, and organ damage. The cumulative burden makes survival into adulthood very unlikely without intervention.

1. Clinical suspicion based on the pattern above.
2. Laboratory clues: high IgE/eosinophils; T-cell lymphopenia; impaired antibody responses.
3. Flow cytometry for DOCK8 protein (screening) and confirmatory genetic testing.

Supportive care (now): People with DOCK8 often need infection prophylaxis, IV or subcutaneous immunoglobulin, and intensive skin/eczema management. These measures reduce infections and improve quality of life but do not correct the underlying immune defect.
PubMed

Targeted symptom control: In select cases, dupilumab has helped severe eczema and eczema herpeticum in DOCK8 deficiency, based on case reports. It treats symptoms but is not a cure. Decisions must be made by the treating specialists.
PMC

Curative option (path to normal immunity): Hematopoietic stem cell transplantation (HSCT) is the only known curative treatment for DOCK8 deficiency. Outcomes are best in experienced centers and when performed before severe complications accumulate. International series report ~80–85% overall survival after HSCT, and studies show restoration of immune function post-transplant.
JCI Insight
PMC
AstCT Journal
AstCT Journal (2)

Why timing matters: Without HSCT, long-term survival is significantly reduced due to recurrent infections and complications; early referral to transplant programs is recommended in many reports.

Extreme infection risk: DOCK8 patients have persistent viral and fungal infections, which make the pre- and post-transplant phases especially dangerous.

Donor search: A full 10/10 HLA match is ideal but rare. In DOCK8, even mismatched donors (haploidentical transplants) have been attempted, but outcomes are poorer without the highest-level expertise.

Immune reconstitution: It can take 1–2 years for a new immune system to rebuild, during which time the children remain extremely vulnerable.

Graft-versus-host disease (GVHD): Occurs when donor immune cells attack the recipient’s body. GVHD can affect skin, liver, gut, and lungs — sometimes fatally.

In large international studies, survival rates after transplantation are very encouraging:

Aydin et al. (Blood, 2019) reported an 84% overall survival rate among 81 patients who underwent HSCT for DOCK8 deficiency, particularly when performed before severe complications developed.

Al-Zahrani et al. (J Allergy Clin Immunol, 2020) found similarly high survival outcomes, with most patients achieving durable immune reconstitution and reduced infection rates.

These studies show that, while the transplant is complex and risky, it offers the only path to long-term survival and a future beyond DOCK8.

Hospitalization: Children typically spend 2–4 months in hospital, sometimes longer for DOCK8 patients due to pre-existing infections.

Protective isolation: Strict infection precautions are required during the first critical months, often in HEPA-filtered rooms. Even after discharge, contact with public spaces and schools is delayed until the immune system stabilizes.

Medications: Antiviral, antifungal, and antibacterial prophylaxis are given for many months; immunosuppressants are required to prevent or treat graft-versus-host disease. Blood transfusions are common in the early post-transplant phase until the new marrow is producing healthy cells.

Monitoring: The new immune system is carefully tracked using blood tests for immune cell recovery, donor chimerism, and viral PCR monitoring. IgE levels — often extremely high in DOCK8 — usually fall after successful engraftment.

Long-term follow-up: Even after leaving hospital, regular clinic visits continue for years to monitor immune function, manage GVHD, and prevent late complications.